ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non–small cell lung cancer
- 1 February 2002
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (1) , 37-46
- https://doi.org/10.1053/sonc.2002.31521
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptorLung Cancer, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Evaluation of HER2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization (FISH)Lung Cancer, 2000
- Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinomaLung Cancer, 2000
- Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression andin vitro invasionInternational Journal of Cancer, 2000
- Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomasBritish Journal of Cancer, 1998
- Relationship of p53 molecular abnormalities with flow cytometry and growth factor receptor content in lung cancerClinica Chimica Acta; International Journal of Clinical Chemistry, 1998
- A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancerEuropean Journal Of Cancer, 1996
- Epidermal growth factor receptors in lung tumoursThe Journal of Pathology, 1987
- Expression of epidermal growth factor receptor (EGF-R) in human lung tumoursBritish Journal of Cancer, 1986